scholarly journals Quality of life and its association with direct medical costs for COPD in urban China

2015 ◽  
Vol 13 (1) ◽  
Author(s):  
Minmin Wu ◽  
Qi Zhao ◽  
Yue Chen ◽  
Chaowei Fu ◽  
Biao Xu
Keyword(s):  
Quality Of Life ◽  
Medical Costs ◽  
Urban China ◽  
Direct Medical Costs

scholarly journals Inflammatory Bowel Disease: A Canadian Burden of Illness Review

2012 ◽  
Vol 26 (11) ◽  
pp. 811-817 ◽  
Author(s):  
Angela Rocchi ◽  
Eric I Benchimol ◽  
Charles N Bernstein ◽  
Alain Bitton ◽  
Brian Feagan ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Health Care ◽  
Burden Of Illness ◽  
Indirect Costs ◽  
Medical Costs ◽  
Patient Costs ◽  
Direct Medical Costs ◽  
Inflammatory Bowel ◽  
Incident Cases

BACKGROUND: Inflammatory bowel diseases (IBD) – Crohn’s disease (CD) and ulcerative colitis (UC) – significantly impact quality of life and account for substantial costs to the health care system and society.OBJECTIVE: To conduct a comprehensive review and summary of the burden of IBD that encompasses the epidemiology, direct medical costs, indirect costs and humanistic impact of these diseases in Canada.METHODS: A literature search focused on Canadian data sources. Analyses were applied to the current 2012 Canadian population.RESULTS: There are approximately 233,000 Canadians living with IBD in 2012 (129,000 individuals with CD and 104,000 with UC), corresponding to a prevalence of 0.67%. Approximately 10,200 incident cases occur annually. IBD can be diagnosed at any age, with typical onset occurring in the second or third decade of life. There are approximately 5900 Canadian children <18 years of age with IBD. The economic costs of IBD are estimated to be $2.8 billion in 2012 (almost $12,000 per IBD patient). Direct medical costs exceed $1.2 billion per annum and are driven by cost of medications ($521 million), hospitalizations ($395 million) and physician visits ($132 million). Indirect costs (society and patient costs) total $1.6 billion and are dominated by long-term work losses of $979 million. Compared with the general population, the quality of life patients experience is low across all dimensions of health.CONCLUSIONS: The present review documents a high burden of illness from IBD due to its high prevalence in Canada combined with high per-patient costs. Canada has among the highest prevalence and incidence rates of IBD in the world. Individuals with IBD face challenges in the current environment including lack of awareness of IBD as a chronic disease, late or inappropriate diagnosis, inequitable access to health care services and expensive medications, diminished employment prospects and limited community-based support.

Comparison of Out-of-Pocket Costs and Quality of Life (QOL) for Patients (pts) with Hodgkin’s Disease (HD), Indolent Non-Hodgkin’s Lymphoma (INHL) and Aggressive Non-Hodgkin’s Lymphoma (ANHL).

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 3332-3332
Author(s):  
Narissa J. Nonzee ◽  
Sheila O. Brown ◽  
Chih-Hung Chang ◽  
Andrew M. Evens ◽  
Leo I. Gordon ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Hodgkin’S Lymphoma ◽  
Medical Costs ◽  
Hodgkin's Lymphoma ◽  
Cancer Type ◽  
Direct Medical Costs ◽  
Treatment Type ◽  
Out Of Pocket Costs ◽  
Time Since Diagnosis

Abstract BACKGROUND: We report preliminary results from a study on the out-of-pocket costs (cancer related costs not covered by healthcare insurance) for 57 lymphoma pts. To explore factors that influence out-of-pocket costs and QOL, cancer type, stage, time since diagnosis (Dx), treatment type (with or without rituximab), and age were evaluated. METHODS: Lymphoma pts provided information on out-of-pocket costs for 3-month periods after lymphoma Dx and completed the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) QOL measure. Monthly costs were evaluated. Direct medical costs are costs related to medications, hospital bills, and doctor visits. Direct non-medical costs are peripheral costs related to transportation, meals, and telephone calls. RESULTS: The majority of lymphoma pts were Caucasian (87%), married (63%), ≤ 55 years old (58%), and employed (40%). All pts were undergoing active treatment and had healthcare insurance coverage. 62% of pts had stage I-III lymphoma, 35% had stage IV, and 3% had unknown stage. Mean monthly total out-of-pocket costs for all 57 lymphoma pts were $818. Direct medical costs for HD pts were 3.2 and 1.4-fold higher than for INHL and ANHL pts, respectively. Direct non-medical costs were highest for ANHL. Total costs for pts < 6 months since Dx were 1.5 and 2.2-fold higher than for pts 6–12 and > 12 months since Dx, respectively. Total costs for pts undergoing treatment without rituximab were 1.5-fold higher than costs for pts with rituximab. Pts ≤ 55 years old had 1.4-fold higher costs than pts > 55 years old. QOL for pts < 6 months since Dx was greater than for pts ≥ 6 months since Dx (p-value =0.02). CONCLUSION: The mean monthly out-of-pocket costs were greatest for HD ($1,136), followed by ANHL ($847) and INHL ($447), and were driven primarily by direct medical costs. Though pts < 6 months since Dx incurred higher total costs than pts ≥ 6 months since Dx, their QOL measures were better. It is important to evaluate costs and quality of life of pts with cancer when describing the economic and psychosocial burden of cancer. Direct Medical, Direct Non-medical, and Total (Medical & Non-medical) Mean Out-of-Pocket Cost per Month N Direct Medical Out-of-Pocket Cost ($/month) Direct Non-medical Out-of-Pocket Cost ($/month) Total Out-of-Pocket Cost ($/month) All Patients 57 647 171 818 Cancer Type Hodgkin’s Lymphoma 16 972 164 1,136 Aggressive NHL 24 671 176 847 Indolent NHL 17 307 170 477 Time since diagnosis <6 months 28 893 165 1,058 6–12 months 13 494 215 709 >12 months 16 341 146 487 Treatment Type With Rituximab 36 543 143 686 Without Rituximab 21 825 219 1,044 Age <=55 yrs old 33 734 188 923 >55 yrs old 24 527 146 673 Quality of Life of Lymphoma Patients N FACT-Lymphoma Score p-value All Patients 60 126 Cancer Type 0.65 Hodgkin’s Lymphoma 17 126 Aggressive NHL 25 128 Indolent NHL 18 121 Cancer Stage 0.37 I–III 37 124 IV 21 126 N/R 2 149 Time since diagnosis 0.02 <6 months 29 134 6–12 months 15 116 >12 months 16 118 Age 0.28 <=55 yrs old 35 122 >55 yrs old 25 129

scholarly journals PIN159 Factors Associated with Health-Related Quality of Life and Medical Costs of People Living with HIV in Italy

2020 ◽  
Vol 23 ◽  
pp. S570
Author(s):  
E. Foglia ◽  
B. Menzaghi ◽  
G. Rizzardini ◽  
E. Garagiola ◽  
L.B. Ferrario ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Medical Costs ◽  
People Living With Hiv ◽  
Health Related Quality ◽  
Factors Associated ◽  
Related Quality ◽  
Health Related ◽  
Living With Hiv

scholarly journals Assessment of dialysis initiation by a fuzzy mathematics equation (ADIFE): a study protocol for a randomised controlled trial

BMJ Open ◽  
2019 ◽  
Vol 9 (9) ◽  
pp. e023162
Author(s):  
Jilin Chen ◽  
Ying Liu ◽  
Xiangmei Chen ◽  
Xuefeng Sun ◽  
Wei Li ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Randomised Controlled Trial ◽  
Short Form ◽  
Controlled Trial ◽  
Medical Costs ◽  
Dialysis Initiation ◽  
Fuzzy Mathematics ◽  
Late Start ◽  
Randomised Controlled

IntroductionStarting dialysis early or late both result in a low quality of life and a poor prognosis in patients undergoing haemodialysis. However, there remains no consensus on the optimal timing of dialysis initiation, mainly because of a lack of suitable methods to assess variations in dialysis initiation time. We have established a novel equation named DIFE (Dialysis Initiation based on Fuzzy-mathematics Equation) through a retrospective, multicentre clinical cohort study in China to determine the most suitable timing of dialysis initiation. The predictors of the DIFE include nine biochemical markers and clinical variables that together influence dialysis initiation. To externally validate the clinical accuracy of DIFE, we designed the assessment of DIFE (ADIFE) study as a prospective, open-label, multicentre, randomised controlled trial to assess the clinical outcomes among patients who initiate dialysis in an optimal start dialysis group and a late-start dialysis group, based on DIFE.Methods and analysisA total of 388 enrolled patients with end-stage renal disease will be randomised 1:1 to the optimal start dialysis group, with a DIFE value between 30 and 35, or the late-start dialysis group, with a DIFE value less than 30, using the Randomization and Trial Supply Management system. Participants will be assessed for changes in signs and symptoms, dialysis mode and parameters, biochemical and inflammatory markers, Subjective Global Assessment, Kidney Disease Quality of Life Short Form, Cognitive Assessment, medical costs, adverse events and concomitant medication at baseline, predialysis visiting stage and postdialysis visiting stage, every 12–24 weeks. The following data will be recorded on standardised online electronic case report forms. The primary endpoint is 3-year all-cause mortality. The secondary endpoints include non-fatal cerebrocardiovascular events, annual hospitalisation rate, quality of life, medical costs and haemodialysis related complications.Ethics and disseminationEthical approval was obtained from the Ethics Committee of the First Affiliated Hospital of Dalian Medical University China (registration no: YJ-KY-2017–119) and the ethics committees of all participating centres. The final results of the ADIFE trial will be presented to the study sponsor, clinical researchers and the patient and public involvement reference group. Findings will be disseminated through peer-reviewed journals, Clinical Practice Guidelines and at scientific meetings.Trial registration numberClinicalTrial.gov. Registry (NCT03385902); pre-results.

A Concept of Preventive Medicine

1976 ◽  
Vol 6 (4) ◽  
pp. 327-329
Author(s):  
Ernest B. Luongo
Keyword(s):  
Quality Of Life ◽  
Health Care ◽  
Preventive Medicine ◽  
Allied Health ◽  
Health Professions ◽  
Medical Costs ◽  
Self Control ◽  
Allied Health Professions ◽  
Positive Quality

Preventive Medicine as it relates to a positive “quality of life” must be given top priority. With soaring medical costs of health care, allied health professions must place much more concern on innovative and creative ways to reduce or eliminate situations that may endanger an individual's health. If individuals, through self control, can begin to master their own destiny then the concept of Preventive Medicine may begin to be internalized by humankind.

Sign in / Sign up

Export Citation Format

Share Document